122 related articles for article (PubMed ID: 37413906)
1. Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine.
Shiota Sato Y; Elbadawy M; Suzuki K; Tsunedomi R; Nagano H; Ishihara Y; Yamamoto H; Azakami D; Uchide T; Fukushima R; Tanaka R; Yoshida T; Mori T; Abugomaa A; Kaneda M; Yamawaki H; Shinohara Y; Aboubakr M; El-Asrag ME; Usui T; Sasaki K
Biomed Pharmacother; 2023 Sep; 165():115079. PubMed ID: 37413906
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a novel experimental model for muscle-invasive bladder cancer using a dog bladder cancer organoid culture.
Elbadawy M; Usui T; Mori T; Tsunedomi R; Hazama S; Nabeta R; Uchide T; Fukushima R; Yoshida T; Shibutani M; Tanaka T; Masuda S; Okada R; Ichikawa R; Omatsu T; Mizutani T; Katayama Y; Noguchi S; Iwai S; Nakagawa T; Shinohara Y; Kaneda M; Yamawaki H; Sasaki K
Cancer Sci; 2019 Sep; 110(9):2806-2821. PubMed ID: 31254429
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer.
Yoshimoto S; Kato D; Kamoto S; Yamamoto K; Tsuboi M; Shinada M; Ikeda N; Tanaka Y; Yoshitake R; Eto S; Saeki K; Chambers J; Hashimoto Y; Uchida K; Nishimura R; Nakagawa T
J Vet Med Sci; 2020 Jun; 82(6):804-808. PubMed ID: 32249253
[TBL] [Abstract][Full Text] [Related]
4. Establishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method.
Sato Y; Elbadawy M; Suzuki K; Tsunedomi R; Nagano H; Ishihara Y; Yamamoto H; Azakami D; Uchide T; Nabeta R; Fukushima R; Abugomaa A; Kaneda M; Yamawaki H; Shinohara Y; Usui T; Sasaki K
Biomed Pharmacother; 2023 Jun; 162():114651. PubMed ID: 37030135
[TBL] [Abstract][Full Text] [Related]
5. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
[TBL] [Abstract][Full Text] [Related]
6. Derivation of adult canine intestinal organoids for translational research in gastroenterology.
Chandra L; Borcherding DC; Kingsbury D; Atherly T; Ambrosini YM; Bourgois-Mochel A; Yuan W; Kimber M; Qi Y; Wang Q; Wannemuehler M; Ellinwood NM; Snella E; Martin M; Skala M; Meyerholz D; Estes M; Fernandez-Zapico ME; Jergens AE; Mochel JP; Allenspach K
BMC Biol; 2019 Apr; 17(1):33. PubMed ID: 30975131
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.
Miura A; Yamada D; Nakamura M; Tomida S; Shimizu D; Jiang Y; Takao T; Yamamoto H; Suzawa K; Shien K; Yamane M; Sakaguchi M; Toyooka S; Takarada T
Int J Cancer; 2021 Oct; 149(8):1593-1604. PubMed ID: 34152598
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
Ma X; Yang S; Jiang H; Wang Y; Xiang Z
J Transl Med; 2021 Aug; 19(1):368. PubMed ID: 34446056
[TBL] [Abstract][Full Text] [Related]
9. Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report.
Bie Y; Wang J; Xiong L; Wang D; Liao J; Zhang Y; Lin H
Medicine (Baltimore); 2021 Mar; 100(11):e24793. PubMed ID: 33725945
[TBL] [Abstract][Full Text] [Related]
10. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.
Elbadawy M; Sato Y; Mori T; Goto Y; Hayashi K; Yamanaka M; Azakami D; Uchide T; Fukushima R; Yoshida T; Shibutani M; Kobayashi M; Shinohara Y; Abugomaa A; Kaneda M; Yamawaki H; Usui T; Sasaki K
Cancer Biol Ther; 2021 Jun; 22(5-6):357-371. PubMed ID: 34034619
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a direct 2.5D organoid culture model using companion animal cancer tissues.
Abugomaa A; Elbadawy M; Yamamoto H; Ayame H; Ishihara Y; Sato Y; Yamawaki H; Kaneda M; Usui T; Sasaki K
Biomed Pharmacother; 2022 Oct; 154():113597. PubMed ID: 36030590
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A; Cooper JE; Myrta S; Wongchenko MJ; Lin E; Long JE; Foreman O; Modrusan Z; Tremayne JR; de la Cruz CC; Merchant M; Martin SE; Yan Y; Junttila MR
Clin Cancer Res; 2021 Feb; 27(4):1162-1173. PubMed ID: 33023953
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells.
Usui T; Sakurai M; Nishikawa S; Umata K; Nemoto Y; Haraguchi T; Itamoto K; Mizuno T; Noguchi S; Mori T; Iwai S; Nakagawa T; Yamawaki H; Ohama T; Sato K
Cancer Sci; 2017 Dec; 108(12):2383-2392. PubMed ID: 29024204
[TBL] [Abstract][Full Text] [Related]
15. Identification of Recurrent Activating
Lorch G; Sivaprakasam K; Zismann V; Perdigones N; Contente-Cuomo T; Nazareno A; Facista S; Wong S; Drenner K; Liang WS; Amann JM; Sinicropi-Yao SL; Koenig MJ; La Perle K; Whitsett TG; Murtaza M; Trent JM; Carbone DP; Hendricks WPD
Clin Cancer Res; 2019 Oct; 25(19):5866-5877. PubMed ID: 31431454
[TBL] [Abstract][Full Text] [Related]
16. Protocol for generation of lung adenocarcinoma organoids from clinical samples.
Li Z; Yu L; Chen D; Meng Z; Chen W; Huang W
STAR Protoc; 2021 Mar; 2(1):100239. PubMed ID: 33426535
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.
Kim M; Mun H; Sung CO; Cho EJ; Jeon HJ; Chun SM; Jung DJ; Shin TH; Jeong GS; Kim DK; Choi EK; Jeong SY; Taylor AM; Jain S; Meyerson M; Jang SJ
Nat Commun; 2019 Sep; 10(1):3991. PubMed ID: 31488816
[TBL] [Abstract][Full Text] [Related]
18. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
19. Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma.
Ebisudani T; Hamamoto J; Togasaki K; Mitsuishi A; Sugihara K; Shinozaki T; Fukushima T; Kawasaki K; Seino T; Oda M; Hanyu H; Toshimitsu K; Emoto K; Hayashi Y; Asakura K; Johnson TA; Terai H; Ikemura S; Kawada I; Ishii M; Hishida T; Asamura H; Soejima K; Nakagawa H; Fujii M; Fukunaga K; Yasuda H; Sato T
Cell Rep; 2023 Mar; 42(3):112212. PubMed ID: 36870059
[TBL] [Abstract][Full Text] [Related]
20. Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
Wang CY; Hsia JY; Li CH; Ho CC; Chao WR; Wu MF
Clin Lung Cancer; 2021 Nov; 22(6):e878-e880. PubMed ID: 34148767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
